TY - JOUR
T1 - Treatment options for cyclic vomiting syndrome
AU - Sudel, Boris
AU - Li, B. U.K.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2005/10
Y1 - 2005/10
N2 - Since its initial description nearly two centuries ago, treatment of idiopathic cyclic vomiting syndrome (CVS) remains largely empiric because of its obscure pathogenesis and the paucity of controlled therapeutic trials. Despite these challenges, this report reviews open-label trials, retrospective case series, and upcoming consensus guidelines to update the treatment. The treatment approach to a patient with CVS should include consideration of lifestyle changes including avoidance of potential triggers, prophylactic drug therapy to prevent subsequent episodes, abortive and/or supportive care treatment during acute episodes, and support of the family. The mainstays of drug therapy include antimigraine, anti-emetic, and anticonvulsive medications used for prophylactic, abortive, and supportive therapy, with reported efficacies of between 40% and 90%. Prophylactic antimigraine and anticonvulsive agents are used to prevent episodes. Antimigraine triptans are used to abort episodes. ntiemetic agents can reduce the severity of episodes and are best used in conjunction with sedatives.
AB - Since its initial description nearly two centuries ago, treatment of idiopathic cyclic vomiting syndrome (CVS) remains largely empiric because of its obscure pathogenesis and the paucity of controlled therapeutic trials. Despite these challenges, this report reviews open-label trials, retrospective case series, and upcoming consensus guidelines to update the treatment. The treatment approach to a patient with CVS should include consideration of lifestyle changes including avoidance of potential triggers, prophylactic drug therapy to prevent subsequent episodes, abortive and/or supportive care treatment during acute episodes, and support of the family. The mainstays of drug therapy include antimigraine, anti-emetic, and anticonvulsive medications used for prophylactic, abortive, and supportive therapy, with reported efficacies of between 40% and 90%. Prophylactic antimigraine and anticonvulsive agents are used to prevent episodes. Antimigraine triptans are used to abort episodes. ntiemetic agents can reduce the severity of episodes and are best used in conjunction with sedatives.
UR - http://www.scopus.com/inward/record.url?scp=28044455021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28044455021&partnerID=8YFLogxK
U2 - 10.1007/s11938-005-0041-9
DO - 10.1007/s11938-005-0041-9
M3 - Review article
C2 - 16162304
AN - SCOPUS:28044455021
SN - 1092-8472
VL - 8
SP - 387
EP - 395
JO - Current Treatment Options in Gastroenterology
JF - Current Treatment Options in Gastroenterology
IS - 5
ER -